BioGaia appoints new Managing Director

25-Jun-2018 - Sweden

The Board of BioGaia has decided to appoint Isabelle Ducellier as new Managing Director of BioGaia as of November 5, 2018. Isabelle is today a member of the Board of BioGaia and General Secretary of the Swedish Childhood Cancer Fund.

Previously, Isabelle Ducellier has held a number of senior international positions within the Pernod Ricard Group for 20 years, mainly within sales and marketing. She completed her career there as CEO and Board member of Pernod Ricard Sweden and successfully led the integration of Vin & Sprit AB into the Group. After that, she has been a partner and consultant at McKinsey Sweden, among other things in the fields of advanced digital marketing, mergers and acquisitions. In addition to a Master's degree in International Marketing Isabelle has also completed Executive MBA programs at both Harvard and INSEAD.

"We are very pleased that we have been able to recruit Isabelle. She has extensive knowledge and a solid international experience of leading positions in sales and consumer marketing, which has become an increasingly important component of our business development. Isabelle also has the intellectual curiosity and energy needed to be able to embark on the advanced research in our business areas including the microbiome field. Here, her experiences from the Swedish Childhood Cancer Fund are also well-suited," says Peter Rothschild, Chairman of the Board at BioGaia.

"I am very happy about this appointment and look forward to contributing with my special skills to BioGaia’s already very successful business model,” says Isabelle Ducellier, future Managing Director of BioGaia.

As previously announced, BioGaia's current Managing Director terminates his employment June 30. From this point until November 5, when Isabelle can leave her assignment at the Swedish Childhood Cancer Fund, Sebastian Schröder is Acting Managing Director.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?